Altimmune (NASDAQ:ALT) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.
Risk & Volatility
Altimmune has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.
Valuation & Earnings
This table compares Altimmune and NGM Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Altimmune | $5.80 million | 81.15 | $-20,520,000.00 | ($0.98) | -12.93 |
NGM Biopharmaceuticals | $103.54 million | 18.10 | $-42,790,000.00 | ($0.85) | -28.74 |
Altimmune has higher earnings, but lower revenue than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations for Altimmune and NGM Biopharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Altimmune | 0 | 0 | 6 | 0 | 3.00 |
NGM Biopharmaceuticals | 0 | 0 | 5 | 2 | 3.29 |
Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. NGM Biopharmaceuticals has a consensus price target of $39.1111, suggesting a potential upside of 60.09%. Given Altimmune's higher probable upside, equities research analysts clearly believe Altimmune is more favorable than NGM Biopharmaceuticals.
Insider & Institutional Ownership
66.2% of Altimmune shares are owned by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 2.7% of Altimmune shares are owned by insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Altimmune and NGM Biopharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Altimmune | -659.33% | -46.39% | -38.32% |
NGM Biopharmaceuticals | -91.64% | -29.47% | -25.58% |
Summary
NGM Biopharmaceuticals beats Altimmune on 9 of the 15 factors compared between the two stocks.